Brought to you by 
Intrexon, Oragenics ally in the development of antibiotics
30 Jan 2023
Executive Summary
Probiotics developer Oragenics Inc. will use synthetic biology firm Intrexon Corp.’s transgene and cell engineering platforms--such as UltraVector--in the development of lantibiotics as APIs for treating infectious diseases.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
- Transgenics
-
Drug Discovery Technologies
- Genomics-Proteomics
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Intrexon, Oragenics ally in the development of antibiotics
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice